Skip to main content
Premium Trial:

Request an Annual Quote

Degussa Corp. to Take Full Control of Proligo

NEW YORK, Aug. 22 – Gilead Sciences is selling its 49 percent interest in oligonucleotides manufacturer Proligo to Degussa Corporation, which currently holds the remaining Proligo shares, the company announced on Wednesday.

The deal, expected to close on Aug. 31, is for $14 million in cash, according to Foster City, Calif.-based Gilead.

Proligo is a joint venture between Gilead and SKW Americas, a subsidiary of Parsippany, NJ-based Degussa. Proligo of Boulder, Colo. sells standard and specialty monomers for oligonucleotide synthesis and probes. Degussa was entitled to purchase Gilead’s interest in Proligo as part of the terms of Gilead’s 1998 merger with NeXstar Pharmaceuticals, which originally formed Proligo in a joint venture with SKW Americas.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.